Cargando…

Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery

BACKGROUND AND AIMS: Platelet‐stored serotonin critically affects liver regeneration in mice and humans. Selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitors (SNRIs) reduce intraplatelet serotonin. As SSRIs/SNRIs are now one of the most commonly prescribed d...

Descripción completa

Detalles Bibliográficos
Autores principales: Starlinger, Patrick, Pereyra, David, Hackl, Hubert, Ortmayr, Gregor, Braunwarth, Eva, Santol, Jonas, Najarnia, Sina, Driedger, Michael R., Gregory, Lindsey, Alva‐Ruiz, Roberto, Glasgow, Amy, Assinger, Alice, Nagorney, David M., Habermann, Elizabeth B., Staetttner, Stefan, Cleary, Sean P., Smoot, Rory L., Gruenberger, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251772/
https://www.ncbi.nlm.nih.gov/pubmed/33078426
http://dx.doi.org/10.1002/hep.31601
_version_ 1783717159048839168
author Starlinger, Patrick
Pereyra, David
Hackl, Hubert
Ortmayr, Gregor
Braunwarth, Eva
Santol, Jonas
Najarnia, Sina
Driedger, Michael R.
Gregory, Lindsey
Alva‐Ruiz, Roberto
Glasgow, Amy
Assinger, Alice
Nagorney, David M.
Habermann, Elizabeth B.
Staetttner, Stefan
Cleary, Sean P.
Smoot, Rory L.
Gruenberger, Thomas
author_facet Starlinger, Patrick
Pereyra, David
Hackl, Hubert
Ortmayr, Gregor
Braunwarth, Eva
Santol, Jonas
Najarnia, Sina
Driedger, Michael R.
Gregory, Lindsey
Alva‐Ruiz, Roberto
Glasgow, Amy
Assinger, Alice
Nagorney, David M.
Habermann, Elizabeth B.
Staetttner, Stefan
Cleary, Sean P.
Smoot, Rory L.
Gruenberger, Thomas
author_sort Starlinger, Patrick
collection PubMed
description BACKGROUND AND AIMS: Platelet‐stored serotonin critically affects liver regeneration in mice and humans. Selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitors (SNRIs) reduce intraplatelet serotonin. As SSRIs/SNRIs are now one of the most commonly prescribed drugs in the United States and Europe and given serotonin’s impact on liver regeneration, we evaluated whether perioperative use of SSRIs/SNRIs affects outcome after hepatic resection. APPROACH AND RESULTS: Consecutive patients undergoing hepatic resection (n = 754) were retrospectively included from prospectively maintained databases from two European institutions. Further, an independent cohort of 495 patients from the United States was assessed to validate our exploratory findings. Perioperative intake of SSRIs/SNRIs was recorded, and patients were followed up for postoperative liver dysfunction (LD), morbidity, and mortality. Perioperative intraplatelet serotonin levels were significantly decreased in patients receiving SSRI/SNRI treatment. Patients treated with SSRIs/SNRIs showed a higher incidence of morbidity, severe morbidity, LD, and LD requiring intervention. Associations were confirmed in the independent validation cohort. Combined cohorts documented a significant increase in deleterious postoperative outcome (morbidity odds ratio [OR], 1.56; 95% confidence interval [CI], 1.07‐2.31; severe morbidity OR, 1.86; 95% CI, 1.22‐2.79; LD OR, 1.96; 95% CI, 1.23‐3.06; LD requiring intervention OR, 2.22; 95% CI, 1.03‐4.36). Further, multivariable analysis confirmed the independent association of SSRIs/SNRIs with postoperative LD, which was closely associated with postoperative 90‐day mortality and 1‐year overall survival. CONCLUSIONS: We observed a significant association of perioperative SSRI/SNRI intake with adverse postoperative outcome after hepatic resection. This indicates that SSRIs/SNRIs should be avoided perioperatively in patients undergoing hepatic resections.
format Online
Article
Text
id pubmed-8251772
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82517722021-07-07 Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery Starlinger, Patrick Pereyra, David Hackl, Hubert Ortmayr, Gregor Braunwarth, Eva Santol, Jonas Najarnia, Sina Driedger, Michael R. Gregory, Lindsey Alva‐Ruiz, Roberto Glasgow, Amy Assinger, Alice Nagorney, David M. Habermann, Elizabeth B. Staetttner, Stefan Cleary, Sean P. Smoot, Rory L. Gruenberger, Thomas Hepatology Original Articles BACKGROUND AND AIMS: Platelet‐stored serotonin critically affects liver regeneration in mice and humans. Selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitors (SNRIs) reduce intraplatelet serotonin. As SSRIs/SNRIs are now one of the most commonly prescribed drugs in the United States and Europe and given serotonin’s impact on liver regeneration, we evaluated whether perioperative use of SSRIs/SNRIs affects outcome after hepatic resection. APPROACH AND RESULTS: Consecutive patients undergoing hepatic resection (n = 754) were retrospectively included from prospectively maintained databases from two European institutions. Further, an independent cohort of 495 patients from the United States was assessed to validate our exploratory findings. Perioperative intake of SSRIs/SNRIs was recorded, and patients were followed up for postoperative liver dysfunction (LD), morbidity, and mortality. Perioperative intraplatelet serotonin levels were significantly decreased in patients receiving SSRI/SNRI treatment. Patients treated with SSRIs/SNRIs showed a higher incidence of morbidity, severe morbidity, LD, and LD requiring intervention. Associations were confirmed in the independent validation cohort. Combined cohorts documented a significant increase in deleterious postoperative outcome (morbidity odds ratio [OR], 1.56; 95% confidence interval [CI], 1.07‐2.31; severe morbidity OR, 1.86; 95% CI, 1.22‐2.79; LD OR, 1.96; 95% CI, 1.23‐3.06; LD requiring intervention OR, 2.22; 95% CI, 1.03‐4.36). Further, multivariable analysis confirmed the independent association of SSRIs/SNRIs with postoperative LD, which was closely associated with postoperative 90‐day mortality and 1‐year overall survival. CONCLUSIONS: We observed a significant association of perioperative SSRI/SNRI intake with adverse postoperative outcome after hepatic resection. This indicates that SSRIs/SNRIs should be avoided perioperatively in patients undergoing hepatic resections. John Wiley and Sons Inc. 2021-03-16 2021-05 /pmc/articles/PMC8251772/ /pubmed/33078426 http://dx.doi.org/10.1002/hep.31601 Text en © 2020 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Starlinger, Patrick
Pereyra, David
Hackl, Hubert
Ortmayr, Gregor
Braunwarth, Eva
Santol, Jonas
Najarnia, Sina
Driedger, Michael R.
Gregory, Lindsey
Alva‐Ruiz, Roberto
Glasgow, Amy
Assinger, Alice
Nagorney, David M.
Habermann, Elizabeth B.
Staetttner, Stefan
Cleary, Sean P.
Smoot, Rory L.
Gruenberger, Thomas
Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery
title Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery
title_full Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery
title_fullStr Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery
title_full_unstemmed Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery
title_short Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery
title_sort consequences of perioperative serotonin reuptake inhibitor treatment during hepatic surgery
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251772/
https://www.ncbi.nlm.nih.gov/pubmed/33078426
http://dx.doi.org/10.1002/hep.31601
work_keys_str_mv AT starlingerpatrick consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery
AT pereyradavid consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery
AT hacklhubert consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery
AT ortmayrgregor consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery
AT braunwartheva consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery
AT santoljonas consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery
AT najarniasina consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery
AT driedgermichaelr consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery
AT gregorylindsey consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery
AT alvaruizroberto consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery
AT glasgowamy consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery
AT assingeralice consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery
AT nagorneydavidm consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery
AT habermannelizabethb consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery
AT staetttnerstefan consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery
AT clearyseanp consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery
AT smootroryl consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery
AT gruenbergerthomas consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery